Ginkgo biloba-EGb 761 / eff Cancer Research Results

EGb 761, Ginkgo biloba-EGb 761: Click to Expand ⟱

Features:

<p>
<strong>EGb 761</strong> is a standardized, purified extract of
<em>Ginkgo biloba</em> leaves developed for medicinal use. It is typically
standardized to approximately <strong>22–27% flavone glycosides</strong> and
<strong>5–7% terpene lactones</strong>, including ginkgolides A, B and C and
bilobalide, while potentially undesirable <strong>ginkgolic acids</strong> are
reduced to very low levels. EGb 761 has antioxidant, mitochondrial,
neuroprotective, vasoregulatory, anti-inflammatory and platelet-activating-factor
antagonist <span class="wphighlight">eff</span>ects and has been studied extensively in cognitive impairment,
dementia and Alzheimer’s disease. Reported mechanisms include reduction of
oxidative stress, stabilization of mitochondrial function, modulation of
neurotransmitter signalling, protection against amyloid-β-associated toxicity,
improved cerebral microcirculation and modulation of inflammatory pathways.
EGb 761 is kept separate from generic <em>Ginkgo biloba</em> supplements
because commercial extracts vary substantially in flavonoid, terpene-lactone
and ginkgolic-acid content and are not necessarily pharmacologically equivalent
to the standardized EGb 761 preparation. EGb 761 is kept separate
from isolated ginkgolides, bilobalide and ginkgolic acids 
</p>

<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12417213/">high PCA content in EGb 761 may contribute to cognitive benefits</a><br>
 bioactive compounds such as terpenoids (Ginkgolides A, B, and C), polyphenols, organic acids, and flavonoids (quercetin, kaempferol, and isorhamnetin). <br>

<a href="https://pubmed.ncbi.nlm.nih.gov/22784423/">EGb 761</a> 
is a dry extract from Ginkgo biloba leaves (35–67:1), extraction solvent acetone
60% (w/w). The extract is adjusted to 22.0–27.0% ginkgo flavonoids and 5.0–7.0% terpene lactones,
consisting of 2.8–3.4% ginkgolides A, B, and C and 2.6–3.2% bilobalide and contains less than 5 ppm
ginkgolic acids<br>

<pre>


Table 1. Protective capacity of individual compounds of EGb 761 in brain cells)
COMPOUNDMEAN (SEM) PROTECTION ( % )
(0.5 mg/ml) (percentage recovery after insult)
Ginkgolide A    8.0±1.9∗∗
Ginkgolide B    33.0±11.2∗
Ginkgolide C    8.5±1.6∗∗
Ginkgolide J    37.0±12.2∗
Bilobalide      36.3±7.7∗∗
Flavonoids      56.4±12.7∗∗∗
</pre>

eff, efficacy: Click to Expand ⟱

Source:

Type:

Power to enhance an anti cancer effect

Scientific Papers found: Click to Expand⟱

7220-

EGb 761,

Ginkgo Biloba Extract Inhibits Metastasis and ERK/Nuclear Factor kappa B (NF-κB) Signaling Pathway in Gastric Cancer

vitro+vivo,

GC,

SGC-7901

mouse model

TumCP↓, TumCMig↓, TumCI↓, p‑ERK↓, NF-kB↓, MMP2↓, eff↑, TumCG↓, TumMeta↓, Dose↝, TumVol↓,

7239-

EGb 761,

Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis

Review,

AD,

*cognitive↑, *eff↑,

7231-

EGb 761,

Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials

Review,

AD,

 2,684 outpatients randomized to receive treatment for 22–26 weeks,

*toxicity↓, *eff↑, *cognitive↑, *other↑, *eff↑,

7222-

EGb 761,

Ginkgo biloba extract EGb 761® in the symptomatic treatment of mild-to-moderate dementia: a profile of its use

Review,

AD,

*cognitive↑, *toxicity↓, *Dose↝, *BioAv↑, *Half-Life↑, *neuroP↑, *Half-Life↝, *Dose↝, *other↝, *eff↑,

7200-

EGb 761,

PCA,

Optimized Ginkgo biloba extract EGb 761®: boosted therapeutic benefits with minimized CYP enzyme interference

*Dose↝, *AChE↓, *GSK‐3β↝, *eff↑, *cognitive↑, *toxicity↓,

Showing Research Papers: 1 to 5 of 5

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5

Pathway results for Effect on Cancer / Diseased Cells:

Functional Outcomes(tgid=23) ⓘ

TumVol↓, 1,
Total Targets: 11

Pathway results for Effect on Normal Cells:

Transcription & Epigenetics(tgid=7) ⓘ

other↑, 1, other↝, 1,

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

GSK‐3β↝, 1,

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1, Dose↝, 3, eff↑, 5, Half-Life↑, 1, Half-Life↝, 1,

Functional Outcomes(tgid=23) ⓘ

cognitive↑, 4, neuroP↑, 1, toxicity↓, 3,
Total Targets: 12

Scientific Paper Hit Count for: eff, efficacy

5 Ginkgo biloba-EGb 761
1 Protocatechuic acid

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:438  Target#:961  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

Ginkgo biloba-EGb 761 / eff Cancer Research Results

Pathway results for Effect on Cancer / Diseased Cells:

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Migration(tgid=13) ⓘ

Immune & Inflammatory Signaling(tgid=16) ⓘ

Drug Metabolism & Resistance(tgid=21) ⓘ

Functional Outcomes(tgid=23) ⓘ

Pathway results for Effect on Normal Cells:

Transcription & Epigenetics(tgid=7) ⓘ

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Synaptic & Neurotransmission(tgid=18) ⓘ

Drug Metabolism & Resistance(tgid=21) ⓘ

Functional Outcomes(tgid=23) ⓘ

Home Page